These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26164790)

  • 1. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
    Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
    Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
    Fukuyama T; Ehling S; Cook E; Bäumer W
    J Pharmacol Exp Ther; 2015 Sep; 354(3):394-405. PubMed ID: 26159873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.
    Fukuyama T; Ganchingco JR; Bäumer W
    Eur J Pharmacol; 2017 Jan; 794():20-26. PubMed ID: 27847179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
    Abdulrahim H; Sharlala H; Adebajo AO
    Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
    Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
    Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tofacitinib].
    Döker S; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
    Fukuyama T; Ehling S; Wilzopolski J; Bäumer W
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):37. PubMed ID: 29970189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
    Purohit VS; Ports WC; Wang C; Riley S
    J Clin Pharmacol; 2019 Jun; 59(6):811-820. PubMed ID: 30556911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
    Vuitton L; Koch S; Peyrin-Biroulet L
    Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging safety profile of JAK inhibitors in rheumatic disease.
    Winthrop KL
    Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
    Bannwarth B; Kostine M; Poursac N
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Janus kinase antagonists in inflammatory bowel disease.
    Boland BS; Sandborn WJ; Chang JT
    Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.